Combination of clopidogrel and aspirin for reduction of vascular events in patients with atrial fibrillation

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 7, 2009, Pages 749-753

  Kantharia, Bharat K ^a,b   Shah, Arti N ^c  

^a MEMORIAL HERMANN HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c ELMHURST HOSPITAL CENTER   (United States)

Author keywords

ACTIVE A; Aspirin; Atrial fibrillation; Clopidogrel; Stroke; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; CLOPIDOGREL; PLACEBO;

BLEEDING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; NOTE; OUTCOME ASSESSMENT; RECOMMENDED DRUG DOSE; RISK REDUCTION; STROKE; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE; VASCULAR DISEASE;

EID: 70449927843     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.63     Document Type: Note

References (26)

1. The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N. Engl. J. Med. 360(20), 2066-2078 (2009).
2. Feinberg WM, Blackshear JL, Laupacis A et al. Prevalence, age distribution, and gender of patients with atrial fibrillation analysis and implications. Arch. Intern. Med. 155 (5), 469-473 (1995).
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 22(8), 983-988 (1991).
4. Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet 1(8532), 526-529 (1987). (Pubitemid 17020736)
5. Bogousslavsky J, Van Melle G, Regli F, Kappenberger L. Pathogenesis of anterior circulation stroke in patients with nonvalvular atrial fibrillation: the Lausanne Stroke Registry. Neurology 40(7), 1046-1050 (1990). (Pubitemid 20213969)
6. Singer DE, Albers GW, Dalen JE et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133(Suppl.), 546S-592S (2008).
7. Fuster V, Rydén LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). J. Am. Coll. Cardiol. 48, 854-906 (2006) [Erratum, J. Am. Coll. Cardiol. 50, 562 (2007)].
8. The ACTIVE Steering Committee; on behalf of the ACTIVE Investigators. Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Am. Heart J. 151, 1187-1193 (2006).
9. ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367, 1903-1912 (2006).
10. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA 285(22), 2864-2870 (2001). (Pubitemid 32537350)
11. Nagra BS, Kantharia BK. Anticoagulation in nonvalvular atrial fibrillation. Future Cardiol. 1(3), 373-380 (2005).
12. Petersen P, Boysen G, Godtfredsen J et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet 1, 175-178 (1989). (Pubitemid 19038801)
13. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation study: final results. Circulation 84, 527-539 (1991).
14. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N. Engl. J. Med. 323, 1505-1511 (1990).
15. Connolly S, Laupacis A, Gent M et al. Canadian atrial fibrillation anticoagulation (CAFA) study. J. Am. Coll. Cardiol. 18, 349-355 (1991).
16. Ezekowitz M, Bridgers S, James K et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N. Engl. J. Med. 327, 1406-1412 (1992).
17. Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 342(8882), 1255-1262 (1993).
18. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann. Intern. Med. 131, 492-501 (1999) (Pubitemid 29482392)
19. Reynolds MW, Fahrbach K, Hauch O et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation - a systematic review and metaanalysis. Chest 126, 1938-1945 (2004).
20. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345, 494-502 (2001).
21. Bhatt DL, Fox KAA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic disease. N. Engl. J. Med. 354, 1706-1717 (2006).
22. Hart RG, Bhatt DL, Hacke W et al.; for the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. Cerebrovasc. Dis. 25, 344-347 (2008). (Pubitemid 351555858)
23. Lorenzoni R, Lazzerini G, Cocci F, De Caterina R. Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. Am. Heart J. 148, 1, 11-18 (2004).
24. Turpie AGG. New oral anticoagulants in atrial fibrillation. Eur. Heart J. 29, 155-165 (2007).
25. Fountain RB, Holmes DR, Chandrasekaran K et al. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) trial. Am. Heart J. 151, 956-961 (2006).
26. Friedman PA, Asirvatham SJ, Dalegrave C et al. Percutaneous epicardial left atrial appendage closure: preliminary results of an electrogram guided approach. J. Cardiovasc. Electrophysiol. DOI: 10.1111/j.1540-8167.2009.01465.x (2009) (Epub ahead of print).